Inovio Pharmaceuticals (INO) Interest & Investment Income (2011 - 2026)
Inovio Pharmaceuticals (INO) posted Interest & Investment Income of $439593.0 for Q1 2026, down 2.17% sequentially from $449337.0 in Q4 2025, and down 45.6% YoY from $808077.0 in Q1 2025.
Inovio Pharmaceuticals (INO) Interest & Investment Income (2011 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Interest & Investment Income for 16 years, with the latest figure at $439593.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 45.6% year-over-year to $439593.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 47.69% YoY) and the FY2025 annual result came in at $2.4 million, down 49.23% from the prior year.
- Interest & Investment Income eased to $439593.0 in Q1 2026 per INO's latest filing, from $449337.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.9 million in Q3 2023 and troughed at -$176991.0 in Q2 2022.
- A 5-year average of $504684.7 and a median of $439593.0 in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income slumped 6506.61% in 2022, then surged 1856.08% in 2025.
- Over 5 years, Interest & Investment Income stood at -$176991.0 in 2022, then soared by 1127.82% to $1.8 million in 2023, then slumped by 53.13% to $852587.0 in 2024, then slumped by 47.3% to $449337.0 in 2025, then dropped by 2.17% to $439593.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $439593.0, $449337.0, and $552108.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - | 363,847.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 363,847.00 |
| Mar 31, 2026 | 439,593.00 |
| Dec 31, 2025 | 449,337.00 |
| Sep 30, 2025 | 552,108.00 |
| Jun 30, 2025 | -422.00 |
| Mar 31, 2025 | 808,077.00 |
| Dec 31, 2024 | 852,587.00 |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | -13,322.00 |
| Mar 31, 2024 | -46,016.00 |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | -108,089.00 |
| Mar 31, 2023 | 117,862.00 |
| Jun 30, 2022 | -176,991.00 |
| Mar 31, 2022 | -169,097.00 |
| Jun 30, 2021 | -2,679.00 |
| Mar 31, 2021 | 4,861.00 |
| Jun 30, 2020 | 846,900.00 |
| Mar 31, 2020 | -1.93 Mn |